Meeder Asset Management Inc. Trims Stock Position in Eli Lilly and Company $LLY

Meeder Asset Management Inc. lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 18.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,328 shares of the company’s stock after selling 3,902 shares during the quarter. Meeder Asset Management Inc.’s holdings in Eli Lilly and Company were worth $13,221,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. Citizens Financial Group Inc. RI raised its stake in shares of Eli Lilly and Company by 5.1% during the third quarter. Citizens Financial Group Inc. RI now owns 74,287 shares of the company’s stock worth $56,680,000 after purchasing an additional 3,600 shares during the last quarter. Meeder Advisory Services Inc. increased its holdings in Eli Lilly and Company by 0.9% in the third quarter. Meeder Advisory Services Inc. now owns 17,374 shares of the company’s stock valued at $13,256,000 after buying an additional 147 shares in the last quarter. Alley Investment Management Company LLC boosted its position in Eli Lilly and Company by 0.3% during the third quarter. Alley Investment Management Company LLC now owns 13,101 shares of the company’s stock worth $9,996,000 after purchasing an additional 44 shares in the last quarter. Lodestone Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 16.8% in the 3rd quarter. Lodestone Wealth Management LLC now owns 368 shares of the company’s stock worth $281,000 after buying an additional 53 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its holdings in shares of Eli Lilly and Company by 30.7% in the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 13,191 shares of the company’s stock valued at $10,830,000 after purchasing an additional 3,102 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on LLY shares. Scotiabank started coverage on shares of Eli Lilly and Company in a report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price target for the company. Zacks Research upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 1st. Leerink Partnrs raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. Finally, Wells Fargo & Company increased their price target on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Five investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Buy” and an average target price of $1,169.00.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Nvidia partnership — Lilly and Nvidia will fund a San Francisco Bay Area co‑innovation AI lab with up to $1 billion committed over five years to accelerate AI‑driven drug discovery; the deal boosts Lilly’s AI capabilities and signal‑markets view it as a major productivity/innovation catalyst. Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
• Positive Sentiment: Ventyx acquisition — Markets reacted positively to Lilly’s deal for Ventyx Biosciences (inflammation‑focused assets that could complement Lilly’s GLP‑1 franchise), which investors interpret as strategic bolt‑on M&A that expands weight‑loss program adjacencies and clinical upside. Eli Lilly Stock Broke Out Following Plan To Acquire Ventyx Biosciences
• Positive Sentiment: Manufacturing expansion — Lilly’s large Houston manufacturing project (multi‑billion dollar plant) supports production capacity for growing drug volumes and reduces supply risk, a positive for long‑term revenue visibility. Texas seals Eli Lilly’s plans for $7B manufacturing plant in Houston biotech hub
• Positive Sentiment: Supply reassurance for orforglipron — Lilly said it’s confident in supply ahead of expected U.S. approval for its oral weight‑loss candidate, reducing near‑term execution risk around a potential major launch. Lilly says it’s confident weight-loss pill supply ahead of U.S. approval
• Neutral Sentiment: Aktis/AKTS exposure and other biotech bets — Lilly’s equity and collaboration investments (e.g., Aktis) signal diversified R&D exposure but remain speculative and will only move LLY materially if programs hit milestones.
• Neutral Sentiment: Analyst commentary & price forecasts — Several outlets reiterated growth narratives and long‑term forecasts (Zacks, Motley Fool, 24/7 Wall St. pieces), supporting investor sentiment but not immediate fundamentals.
• Negative Sentiment: Competition from Novo Nordisk’s Wegovy pill — The launch of an oral Wegovy competitor increases market competition in the oral weight‑loss category and was earlier cited as the key near‑term headwind that pressured LLY shares. (Market reaction has been mixed as investors weigh competition vs. Lilly’s pipeline and M&A.)

Eli Lilly and Company Stock Up 1.6%

NYSE:LLY opened at $1,080.92 on Tuesday. The business’s fifty day moving average price is $1,040.85 and its 200 day moving average price is $863.67. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The firm has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.88, a PEG ratio of 0.77 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.